RxDoctor Payments Data

Paul Leva, MD

Internal Medicine · Northport, NYNPI 1841222577

Payments from drug & device makers

$12,327in general payments, 2019–2025

Across 529 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$1K
  • Novo Nordisk$1K
  • Amarin Pharma, Inc.$781
  • Sumitomo Pharma America, Inc.$701
  • GSK$591
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$12,322100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,327 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$135,385
Medicare patients
212
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide173$195,478
FarxigaDapagliflozin Propanediol102$76,933
MounjaroTirzepatide50$59,183
TrulicityDulaglutide57$58,677
VascepaIcosapent Ethyl59$43,290
JanumetSitagliptin Phos/Metformin Hcl34$40,621
Repatha SureclickEvolocumab55$36,931
XareltoRivaroxaban35$27,200
JanuviaSitagliptin Phosphate32$27,065
EliquisApixaban26$25,015
LinzessLinaclotide40$24,344
ProliaDenosumab14$23,740
JardianceEmpagliflozin28$22,642
OxycontinOxycodone Hcl28$21,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,039$205,170185 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog Mix 75-25$531$120,580119 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,308$84,560114 claims
MerckJanumet, Januvia, Belsomra$402$76,39388 claims
PfizerEliquis, Abrysvo$259$29,15140 claims
Johnson & JohnsonXarelto$410$27,20035 claims
AbbVieLinzess$157$24,34440 claims
AmgenProlia$1,180$23,74014 claims
Boehringer IngelheimJardiance$29$22,64228 claims
GSKTrelegy Ellipta$591$17,65028 claims
Hikma Pharmaceuticals USAMitigare$13$4,44512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Northport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →